cangrelor tetrasodium NEW
| Price | $39 | $56 | $93 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-19 |
Product Details
| Product Name: cangrelor tetrasodium | CAS No.: 163706-36-3 |
| Purity: 99.15% | Supply Ability: 10g |
| Release date: 2025/07/19 |
Product Introduction
Bioactivity
| Name | cangrelor tetrasodium |
| Description | Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects. |
| In vitro | cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.Cangrelor is also a well-known anti-platelet agent. cangrelor (10 mg/kg) not only significantly decreased BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreased the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice. In addition, cangrelor decreased the number of CD40 and MPO double positive neutrophils and the expression level of CD40 in BLM-treated mouse lungs[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 80 mg/mL (92.56 mM), Sonication is recommended. DMSO : 8.65 mg/mL (10 mM), Sonication is recommended. |
| Keywords | pulmonary | platelet | P2YReceptor | P2Y Receptor | P2Y | intravenous | Inhibitor | inhibit | inflammation | GPR17 | fibrosis | cangrelor tetrasodium | cangrelor | antiplatelet | aggregation |
| Inhibitors Related | Vincamine | Monomethyl fumarate | Questiomycin A | Azathioprine | Uridine 5′-diphosphoglucose disodium salt | CRTh2 antagonist 2 | (±) Clopidogrel hydrogen sulfate | Uridine-5'-diphosphate disodium salt | Benzyl nicotinate | 1-methoxycyclopropanecarboxylic acid | TUG-1375 | Ticagrelor |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-23 | |
| $0.00/1KG |
VIP5Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-09-13 | |
| $999.00/5g |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-09 | |
| $1.00/1g |
Apeloa production Co.,Limited
|
2024-06-11 | ||
| $7.00/1kg |
VIP8Y
|
Career Henan Chemical Co
|
2018-12-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY